Dear Editor,

The appropriate management of patients with inhibitors represents the main challenge for physicians who specialize in haemophilia. Immune tolerance induction (ITI) is the primary therapeutic strategy for achieving inhibitor eradication. ITI represents an intensive and continuous exposure to FVIII until a patient gains complete or partial tolerance against the factor. To contribute to the data from an experienced centre in managing haemophilic patients, the present mixed retrospective and prospective study was aimed to analyse the association between the ITI success rate with a series of clinical variables. The medical records of severe haemophilia A patients from a Congenital Coagulopathies Unit, who started an ITI regimen between March 1980 and July 2015, were reviewed. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.

Eligible subjects included both children and adults diagnosed with severe haemophilia A (FVIII:C <1%) and treated for primary or rescue ITI with plasma-derived FVIII concentrates (pdFVIII), either purified FVIII or von Willebrand factor (VWF)-containing (pdFVIII/VWF), or with recombinant (rFVIII) concentrates. Rescue ITI was defined as the ITI treatments undergone after failure of the primary ITI course. The definitions of ITI success and failure were generally consistent with those currently in use. The time to outcome was measured from initiation of ITI until achievement of success (complete or partial), failure or rescue ITI. The decision of whether ITI was a failure, or to continue ITI treatment longer, was made according to the physician's discretion.

For pharmacokinetic measurements, after 3 days of infused FVIII washing, FVIII:C levels were determined ("pre"). Then, 50 IU/kg FVIII was administered and FVIII:C was determined again after 15 minutes ("post"). 1, 2, 6, 24 and 48 hours (although last 7 years, measurements were taken at three time points: pre, post and 48 hours).

For association analyses, a L1-penalized logistic regression model, LASSO (Least Absolute Shrinkage and Selection Operator), was used. Those variables not penalized to zero were considered as being associated with ITI success. Peak titre was log-transformed before the analyses because of its high right skewness. The use of penalized models is required in cases such as in this study, in which the number of variables was high in relation to the number of assessments.

Kaplan-Meier survival analysis was constructed for the time elapsed in the percentage of patients: (a) reaching inhibitor elimination; (b) reaching a normal FVIII recovery and (c) reaching a normal half-life of infused FVIII. Discrimination by infused FVIII dose (<100 IU/kg/d; ≥100 IU/kg/d) was also made. The generalized Wilcoxon test was used for comparison. Software R (The R Foundation, Vienna, Austria) version 3.2.1 was used for calculations and analysis.

Results showed that 26 patients started an ITI course during the study period. Of these, three patients are still under treatment while 23 ended primary ITI and were therefore evaluated. Data collected were retrospective in patients who started ITI up to year 2000 (n = 11) and prospective after that year (n = 12 patients). Details of patient characteristics and ITI data are shown in Table 1.

Just over half of the patients (n = 13; 57%) started ITI within 1 year after inhibitor diagnostic (47% of complete success [CS]), while in nine patients (39%) the lapse took between 1 and 5 years, and one patient showed an extreme value of 11 years. Eighteen patients (78%) were <5 years old at the time of ITI initiation (50% of CS). The majority of the patients (n = 18; 78%) showed an inhibitor titre <10 BU/mL at start of ITI (55% of CS) but five of them had titre ≥10 BU/mL (60% of CS). Overall, primary ITI success was 57% (13/23 patients), which was lower than that shown in previous studies ranging 63%-100%. A possible reason may be the inclusion of all screened patients in the study, thus mimicking a group with intention of treatment, which has shown a lower success rate. Similarly, premature changes of product type or dose regimen in some patients as well as the high historical inhibitor peak titre in our population could have a role in reducing the chances of success. Nevertheless, less strict criteria than ours for reporting an outcome of successful ITI have been described in other studies and in a registry.

The median time of ITI treatment was 11.4 months (Q1, Q3: 9, 24). Fourteen patients (61%) received pdFVIII (13 pdFVIII/VWF and 1 purified FVIII) for ITI. There was a higher rate of CS in patients treated with pdFVIII (10/14; 71%) rather than those treated with rFVIII (3/9; 33%). Interestingly, the percentage of patients with at

---

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. Haemophilia published by John Wiley & Sons Ltd
TABLE 1  Immune tolerance induction patient data and outcome of ITI

| Patient # | Pre-ITI data | Primary ITI data | Rescue ITI data |
|-----------|--------------|------------------|-----------------|
|           |              |                  |                 |
|           | Historic titre (BU/mL) | Titre at ITI start (BU/mL) | Age at ITI start (y) | Diagnosis to ITI (mo) | Type of FVIII at inhibitor detection | Peak titre (BU/mL) | Duration (mo) | Haemorrhagic events (n) | Type of FVIII | Dosage (IU/kg) | CVC infection | Bypass agent | Immunomodulation | ITI outcome | Type of FVIII | ITI outcome |
|-----------|--------------|------------------|-----------------|
| 1         | 22           | 8                | 25              | 50              | PD                      | 23               | 3              | 0              | PD            | 50/d         | Yes          | No           | No            | CORT         |            | CS            |
| 2         | 41           | 6                | 21              | 132             | PD                      | 41               | 11             | 3              | PD            | 50/d         | Yes          | No           | No            | CORT         |            | CS            |
| 3         | 295          | 50              | 10              | 25              | PD                      | 294             | 28             | 22             | PD            | 50/d         | No           | No           | CORT & PLPH  |            | CS            |
| 4         | 86           | 2                | 8               | 46              | PD                      | 211             | 11             | 13             | PD            | 10 3/wk      | Yes          | No           | No            | F            |            |               |
| 5         | 70           | 32              | 2               | 12              | PD                      | 32               | 33             | 20             | PD            | 50/d         | Yes          | No           | No            | CORT         | CS            |
| 6         | 1075         | 183             | 4               | 32              | PD                      | 1075            | 28             | 12             | PD            | 50/d         | No           | No           | CORT         | F            |               |
| 7         | 14           | 2                | 8               | 55              | PD                      | 2                | 13             | 3              | PD            | 100/d        | No           | No           | CORT         | CS            |
| 8         | 114          | 1                | 2               | 15              | PD                      | 53              | 22             | 3              | PD            | 100/d        | No           | No           | IG            | CS            |
| 9         | 13           | 6                | 4               | 11              | PD                      | 3                | 35             | 12             | PD            | 70/d         | Yes          | No           | CORT         | CS            |
| 10        | 52           | 52              | 0               | 0               | REC                     | 276             | 10             | 1              | REC           | 200/d        | Yes          | No           | IG            | F            | PD           | PS            |
| 11        | 5            | 5                | 2               | 1               | REC                     | 4                | 31             | 13             | REC           | 50 3/wk      | No           | No           | No            | CS            |
| 12        | 7            | 3                | 3               | 12              | PD                      | 723             | 10             | 17             | PD            | 50 3/wk      | No           | No           | No            | F            | PD           | CS            |
| 13        | 2            | 2                | 2               | 5               | REC                     | 1                | 4              | 0              | REC           | 50 3/wk      | No           | No           | No            | CS            |
| 14        | 21           | 2                | 1               | 14              | PD                      | 150              | 12             | 0              | PD            | 200/d        | No           | No           | No            | CS            |
| 15        | 4            | 2                | 4               | 0               | PD                      | 2                | 2              | 2              | REC           | 50 3/wk      | Yes          | No           | No            | F            | PD           | CS            |
| 16        | 13           | 4                | 2               | 3               | REC                     | 3                | 9              | 2              | REC           | 50 3/wk      | No           | Yes          | No            | CS            |
| 17        | 11           | 4                | 1               | 5               | REC                     | 209             | 13             | 16             | REC           | 50 3/wk      | No           | Yes          | No            | F            | PD           | PS            |
| 18        | 134          | 5                | 3               | 10              | REC                     | 340             | 24             | 13             | REC           | 50 3/wk      | No           | Yes          | No            | F            | PD           | Ongoing       |
| 19        | 29           | 1                | 2               | 9               | REC                     | 19               | 10             | 1              | PD            | 133/d        | No           | No           | No            | CS            |
| 20        | 7            | 4                | 0               | 0               | REC                     | 3                | 5              | 1              | REC           | 200/d        | No           | Yes          | No            | F            |              |               |
| 21        | 11           | 11              | 1               | 1               | REC                     | 9                | 11             | 9              | PD            | 80 3/wk      | No           | Yes          | No            | CS            |
| 22        | 10           | 10               | 1               | 1               | REC                     | 3                | 12             | 2              | REC           | 200 3/wk     | No           | No           | No            | F            | PD           | CS            |
| 23        | 24           | 7                | 1               | 0               | REC                     | 24               | 5              | 4              | PD            | 100 3/wk     | No           | Yes          | No            | F            | PD           | Ongoing       |
| Median    | 21.0         | 4.6              | 2.0             | 10.0            | 23.7                     | 12.0            | 3.0            | 2.8            | 9.4           | 1.5          |              |              |              |               |
| Q1        | 10.2         | 2.0              | 1.0             | 1.0             | 2.8                      | 9.4             | 1.5            | 2.8            | 9.4           | 1.5          |              |              |              |               |
| Q3        | 61.0         | 8.8              | 4.0             | 20.0            | 210.0                    | 22.9            | 13.0           | 210.0          | 22.9          | 13.0         |              |              |              |               |

CORT, corticoids; CS, complete success; CVC, central venous catheter; d, days; F, failure; IG, immune globulin; ITI, immune tolerance induction; mo, months; PD, plasma-derived; PLPH, plasmapheresis; PS, partial success; Q1, first quartile; Q3, third quartile; REC, recombinant; wk, weeks; y, years.

aDenotes a risk factor for poor response to ITI: (a) age at start of ITI >7 y old; (b) historical inhibitor peak titre >200 BU; (c) time between inhibitor diagnosis and start of ITI >2 y; and (d) inhibitor titre at start of ITI >10 BU.
The third variable associated with outcome was pdFVIII/VWF infusion although the effect was clinically negligible (7 × 10^{-12}). However, the estimation for this variable was affected by the fact that only one patient out of the 14 patients receiving pdFVIII concentrate did not receive pdFVIII/VWF.

The inverse relation of ITI success rate and the inhibitor peak titre during ITI is supported by the results of other reports.\textsuperscript{2,9,11} However, our study did not find a relationship between ITI success and the historical peak titre, nor the titre at ITI start, as previously reported.\textsuperscript{3,6,9,12}

The effect of the type of concentrate infused was also highlighted by LASSO. A better outcome resulted in patients treated with pdFVIII rather than rFVIII, consistent with previous publications.\textsuperscript{13,14} However, there is some controversy because the use of rFVIII with a good success rate has also been described.\textsuperscript{5,15} Nevertheless, in all cases, comparisons should be made with caution due to the differences in methodologies, protocols and outcome criteria.

The use of pdFVIII/VWF has been reported to improve ITI success.\textsuperscript{7,11} Although in our study the LASSO analysis yielded an extremely small effect associated with pdFVIII/VWF, such statistical effect could not be quantified with accuracy because only one patient out of 14 was not infused with pdFVIII/VWF.

The FVIII dosages given in this study did not influence the ITI outcome. Personalized doses were used, depending on the peak titre of each patient, similar to the procedures applied by other groups.\textsuperscript{12} The Kaplan-Meier analysis showed no statistically significant differences in time to success when comparing the two dose groups established (<100 IU/kg/d; ≥100 IU/kg/d).

Other parameters described to may influence ITI outcome but not found in our patient series were as follows: type of mutation, age at ITI start, delay from inhibitor detection of ITI start and infection at the CVC.\textsuperscript{5,9}

Although the cohort of patients recruited was relatively small and almost half of the patient data were retrospective, which could be considered a study limitation, it is a real-world study; the fact that patients were unselected and all data came from a single centre with consistent routine procedures for more than 20 years confers robustness and homogeneity to the data.

In conclusion, in this study, a high ITI success rate of 86% was found in severe haemophilia A patients from a single centre who were screened over a 25-year period. Moreover, low inhibitor titre peak during ITI and the infusion of pdFVIII were found to be predictors of a higher ITI success rate.

**ACKNOWLEDGEMENTS**

Jordi Bozzo PhD, CMPP (Grifols) is acknowledged for medical writing and editorial support in the preparation of the manuscript, under the direction of the authors. Grifols is a manufacturer of plasmatic FVIII/VWF concentrate.

**DISCLOSURES**

SH has given lectures at educational symposiums organized by Novo Nordisk, Pfizer, Grifols and Baxter; Advisory boards from Shire. CS
has given lectures at educational symposiums organized by Pfizer, Roche, Merck and Astellas. ARC has given lectures at educational symposiums organized by Novo Nordisk, Pfizer, Grifols and Baxter. FQ has received grants from Baxter, Bayer, Pfizer and Novonordisk; has given lectures at educational symposiums organized by Novo Nordisk, Pfizer, Grifols, Bayer, Roche, LFB, Octapharma, Shire, SOBI and CSL Behring; Advisory boards from Pfizer, Bayer, Roche, Shire, LFB, SOBI and CSL Behring. BA, DH, and PC declare no conflict of interests.

AUTHORS’ CONTRIBUTION

SH designed the research study, performed the research, recruited the patients and wrote the paper; CS and PC designed the research study and supervised the study; ARC, BA, FQ and SB recruited the patients and wrote the paper; CS and PC designed the research.

REFERENCES

1. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13(Suppl 1):1-22.

2. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335-1344.

3. Haya S, Lopez MF, Aznar JA, Batlle J. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia. 2001;7:154-159.

4. Kreuz W, EHrenforth S, Funk M, et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia. 1995;1:24-32.

5. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia—principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost. 1994;72:155-158.

6. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood. 1995;86:983-988.

7. Oldenburg J, Jimenez-Yuste V, Peiro-Jordan R, Aledort LM, Santagostino E. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate. Haemophilia. 2014;20:83-91.

8. Rivard GE, Rothschild C, Toll T, Achilles K. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study. Haemophilia. 2013;19:449-455.

9. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002;87:52-57.

10. Gringeri A, Musso R, Mazzucconi MG, et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia. 2007;13:373-379.

11. Kreuz W, Escuriola Ettingshausen C, Vdovin V, et al. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia. 2016;22:87-95.

12. Mathias M, Liesner R, Hann I, Khair K. Immune tolerance in children with factors VIII and IX inhibitors: a single centre experience. Haemophilia. 2005;11:340-345.

13. Kreuz W, Mentzer D, Auerswald G, Becker S, Joseph-Steiner J. Successful immune tolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate. Haemophilia. 1996;6:219.

14. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica. 2005;90:1288-1290.

15. Rocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica. 2006;91:558-561.